Teva Pharmaceutical Industries Ltd., of Jerusalem, said the U.S. Supreme Court has granted the company’s Copaxone (glatiramer acetate) certiorari petition and will hear its appeal of a decision from the U.S. Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the “’808 patent”).